Login to Your Account

Vion Gets SPA Go-Ahead For AML Drug's Phase III

By Randall Osborne

Friday, February 11, 2005
About two weeks after pulling down $32 million to fund its Phase III trial with the sulfonylhydrazine alkylating agent cloretazine in acute myelogenous leukemia, Vion Pharmaceuticals Inc. has reached agreement with the FDA on a special protocol assessment. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription